Skip to main content
. 2020 Dec 2;8(4):720. doi: 10.3390/vaccines8040720

Figure 5.

Figure 5

Cell growth inhibition of human CRC HT-29 and HCT 116 cell lines by losmapimod and doramapimod. HCT-116 and HT-29 CRC cells were treated with DMSO (untreated) or with different doses of losmapimod (LOS) and doramapimod (DORA) for 24, 48, and 72 h. Determination of viable/live cells was carried out by MTT assay as described in Section 2. (a,b) show the dose dependent inhibition of cell growth at 48 and 72 h by losmapimod and doramapimod in HCT-116 cells. Similarly, (c,d) show the dose dependent inhibition in HT-29 cells. The results are shown as mean ± SEM (n = 6); * p-value < 0.005. The dose is on the x-axis, and the viability of cells on y-axis.